adult population as well as among adults with chronic medical conditions. [25] [26] [27] [28] [29] [30] [31] Fitness may play an important independent protective role through its influence on various risk factors for cardiovascular disease such as hypertension, diabetes, and hypercholesterolemia, the development of which could explain the relationship between mortality and low fitness. [32] [33] [34] [35] [36] While earlier studies have underscored the contribution of fitness to clinical outcomes, including disease-related morbidity and mortality, in the general population, no studies have investigated this relationship in SCD.
The objectives of this secondary analysis were to (a) determine the factors associated with baseline exercise capacity in a cohort of adults with SCD and (b) evaluate the relationship of exercise capacity to hospitalization for pain and ACS and overall mortality. We hypothesized that clinical factors such as age, sex, hemoglobin, SCD genotype, and cardiopulmonary disease significantly affect exercise capacity and that reduced exercise capacity is a predictor of more frequent hospitalizations for pain and ACS and higher mortality in adults with SCD.
| ME THODS

| Patient population
A cohort was constructed using data from the Cooperative Study of Sickle Cell Disease (CSSCD), a prospective cohort study designed to investigate the natural history of SCD. The CSSCD cohort has been previously described. 37 Data from participants enrolled in the Phase 2A continuation study were used for this analysis. The Phase 2A continuation study was designed to examine the progression of organ damage in adult CSSCD participants born before January 1, 1956 Excluded from this study were participants who did not complete exercise testing (N = 75) for reasons that were not reported, had exercise data that did not pass quality control for the CSSCD dataset (N = 25), had missing laboratory and/or pulmonary function measurements (N = 9), had contraindications for exercise testing (N = 10), and had missing data related to exercise duration (N = 17) ( Figure 1 ).
| Mortality and follow-up time
Date and cause of death were recorded during Phase 2A follow-up;
however, autopsy information was not routinely available. Follow-up time was computed as the time between the completion of the first exercise test and death, recorded date of final disposition, or September 30, 1993 (the date of the end of Phase 2A data collection), whichever came first.
| Pain and acute chest syndrome hospitalization rates
Vaso-occlusive pain events were defined as previously described (events lasting at least two hours that resulted in a healthcare provider visit and that could not be explained by any other reason than F I G U R E 1 Flow diagram of study participants enrolled in the Cooperative Study of Sickle Cell Disease (CSSCD) and their eligibility for inclusion in the analysis SCD). 38 ACS events were also defined as previously described (a new radiodensity on chest imaging with or without respiratory symptoms accompanied by fever). 39 Rates were defined as the number of events occurring during the follow-up period divided by the total follow-up time.
| Measures of exercise capacity
Data from the first exercise test upon enrollment in Phase 2A were used for this study. Test data were reviewed centrally for quality.
Participants underwent a maximal treadmill test using a modified Balke protocol, which consisted of 10 stages of exercise lasting 2 minutes each. Treadmill speed was kept constant at 2 mph. Incline was initially set at 0% followed by a 2.5% increase at each stage.
Breath-by-breath gas exchange data were not measured during Retrospective pain and ACS rates were defined using follow-up data collected during Phase 1 of CSSCD and calculated over the 3 years prior to exercise testing. Tricuspid regurgitant jet velocity (TRJV) data on echocardiography were not included in our analysis due to a large number of missing values and the inability to confirm standardized procedures for their measurements in the CSSCD.
Data from the pulmonary function testing (PFT) completed closest to the exercise testing date were also used for this study. 
| RE SULTS
| Participant characteristics
A total of 223 African American adults with SCD completed at least 1 exercise test and were followed for an average of 3.1 ± 0.5 years.
Participants (64% female, 70% with hemoglobin SS or S/β 0 thalassemia, mean age 43.3 ± 7.5 years) had mean hemoglobin of Table 1 . Characteristics were not significantly different between groups except that participants who completed exercise testing had longer duration of follow-up, lower annual rate of pain episodes, and lower mortality, when compared with those who did not.
| Exercise capacity in the CSSCD cohort
Participants lasted a mean of 11.6 ± 5.2 minutes on the treadmill with 87% completing ≥3 stages but only 17% reaching stage 9 or 10. Participants' exercise data are summarized in Table 2 . Of the 223 eligible participants who completed first exercise testing, only 100
(45%) completed a second exercise test, which occurred a mean of 2.2 ± 0.5 years after the first. Exercise data were not significantly different between exercise tests (Table 2) . However, more participants reported dyspnea during the second test.
We categorized exercise capacity as low, medium, and high based on tertiles of treadmill duration with an average of 5.7 ± 1.9 minutes in the low tertile, 11.8 ± 1.6 minutes in the intermediate tertile, and 18.1 ± 2.1 minutes in the high tertile (Table 3) .
Across tertiles of exercise capacity, participants in the high tertile were more likely to be males (% males 60 vs 29 vs 23%, P < 0.001), 
| Predictors of baseline exercise capacity
In a multivariable tobit regression model, female sex (β = −3. (Table 6 ). testing. 8, 12, [50] [51] [52] [53] [54] Compared to that in our study, sample sizes in previously published studies have been relatively small. A major challenge to comparing the results from our study to data in other studies is the variability among studies in exercise testing protocols. These differences pertain to required effort (maximal vs submaximal), type of machine (cycle vs treadmill), and whether or not breath-by-breath gas exchange was directly measured. In contrast to ours, other studies have focused on using gas exchange data to characterize cardiopulmonary responses during exercise challenge or on examining the relationship between fitness and specific cardiopulmonary complications such as pulmonary hypertension. 50, 52 Although breath-by-breath gas exchange was not employed as part of the exercise testing performed in the CSSCD study, the Balke treadmill protocol is commonly used in large-scale epidemiology studies of fitness in the general population. [55] [56] [57] Importantly, our study supports the safety of maximal exercise testing using a protocol such as the Balke treadmill test in adults with SCD.
| D ISCUSS I ON
It was not surprising that exercise capacity was low among participants in the CSSCD cohort. Differences in exercise protocols and measurements used to define exercise capacity and fitness across the literature make it difficult to directly compare exercise capacity measured in the CSSCD to that reported in other studies. Whether we use estimated VO 2 max derived from treadmill duration or METS calculated from VO 2 max to define exercise capacity, exercise capacity in the CSSCD cohort was lower compared to levels reported in the literature for the general black population, for which fitness is already known to be lower compared to other race groups. 58 Mean estimated VO 2 max, for example, in the CSSCD participants was lower than that measured even for the lowest fitness group in NHANES study. We found that male sex, lower age, higher Hb, and lower BMI were associated with better exercise capacity in participants in the CSSCD. Although this finding is not surprising given that these variables are known to be associated with fitness in the general population as well as in children and adolescents with sickle cell anemia, it further elucidates the contributions to exercise capacity in adults with SCD, for whom very little is currently known. 9,41,60-62 . We also found that having had an abnormal PFT in the CSSCD was associated with decreased exercise capacity on bivariate analysis and trended toward significance in our multivariable model. This finding is supported by the known relationship between reduced fitness and poor lung function in other disease populations such as COPD or conditions associated with restrictive lung disease. [63] [64] [65] [66] [67] In our analysis, we
were not able to specifically examine the effect of restrictive vs obstructive lung disease on exercise capacity given the number of participants in the CSSCD with mixed patterns on PFT. Nonetheless, our finding that lower FEV 1 itself is independently associated with lower exercise capacity in adults with SCD warrants further investigation as greater annual declines in FEV 1 has also been associated with greater reductions in fitness among young adults in the general population. 68 Our results did not support our hypothesis of an association between exercise capacity and overall mortality. This is in contrast to studies that suggest cardiopulmonary fitness is an important predictor of all-cause mortality in the general population as well as in other chronic conditions. 29, [69] [70] [71] However, the small number of deaths in the CSSCD cohort and relative short follow-up may have affected our ability to discern a relationship. The group of patients with SCD that made it into adulthood during this era or was able to complete maximal exercise testing may also have been inherently healthier.
Although most clinical and laboratory characteristics were not different in patients who did vs did not undergo exercise testing, pain hospitalization rates and mortality were higher in patients who did not complete baseline exercise testing. Nonetheless, it was still valuable to examine the relationship between mortality and exercise capacity despite the possibility for a sampling bias that resulted in a "healthier" group of patients completing exercise testing. More feasible strategies may be needed in SCD to measure exercise capacity such as 6-minute walk distance or submaximal exercise testing, which may improve our ability to evaluate the relationship between exercise capacity and mortality. Finally, low exercise capacity in SCD is multifactorial in etiology and despite the known impact of cardiopulmonary complications on exercise capacity in SCD, mortality The retrospective nature of our analysis may have impacted our interpretation of the exercise test results. In the CSSCD, exercise testing was terminated by volitional exhaustion rather than using more objective criteria to assess maximal efforts such as serum lactate or respiratory exchange ratio. However, maximal heart rates recorded for subjects at the end of exercise testing were on average about 85% of predicted maximal heart rates, which supports the maximal nature of testing in the CCSCD. Although quality control of exercise testing in the CSSCD could not be fully assessed, rigor could in part be assumed given the study's adoption of the modified Balke protocol, a well accepted and validated exercise test, as well as the completeness of the data elements collected during testing.
As breath-by-breath gas exchange data were not collected during exercise testing in the CSSCD study, we could not directly measure VO 2 or analyze specific parameters that allow for a deeper understanding of the cardiopulmonary response to exercise. Nonetheless, we used treadmill duration as a surrogate for exercise capacity and fitness in our study, which represents a common approach used in several other landmark epidemiological studies of fitness.
29,40-43
Finally, given the high degree of missing exercise data from the 2nd tests originally planned for this cohort, we could not assess change in fitness, which compared to baseline fitness may represent a more important risk predictor for mortality in SCD.
Several other limitations of our study warrant discussion.
Participants enrolled in the CSSCD may not accurately reflect a contemporary cohort of adults with SCD given the inception date of the CSSCD, thus reducing the overall generalizability of our findings. The ability to reach adulthood in this era while living with SCD may have introduced a selection or survival bias toward the healthiest adults enrolled in the CSSCD. Moreover, a large number of participants did not undergo exercise testing, and we were unable to determine whether more severe disease precluded some participants from undergoing exercise testing.
Still, our cohort was large enough to include some deaths and more importantly, allowed us to examine other surrogates of disease severity such as pain and ACS hospitalizations. Another limitation of this study was our exclusion of TRJV, a known predictor of mortality in SCD, due to the large number of patients for whom TRJV was unquantifiable. The inability to differentiate unquantifiable from missing values due to technical challenges may explain why TRJV data have been omitted from published studies of CSSCD data to date. We did not look for other evidence of cardiac disease on echocardiography given that measurements required to diagnose diastolic dysfunction, for example, are also prone to technical error and assessing the quality of these measurements was beyond the scope of our analysis. Finally, although elevated N-terminal probrain natriuretic peptide level may be a surrogate marker for pulmonary vascular disease, these data were not publically available through the NHLBI's BioLink dataset for the CSSCD study.
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